Sign up to save your podcasts
Or
Share 340B or Bust: Is This Program Failing the Sick
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
340B or Bust: Is This Program Failing the Sick
🎙️ 340B or Bust: Is This Program Failing the Sick?
This week on Real Pharma, hosts Dr. Na-Ri Oh and Ian Wendt dive into the tangled world of 340B with returning guest William “Bill” Sarraille—one of the most respected voices in healthcare law, an active patient advocate, and a rare disease patient himself.
The 340B Drug Pricing Program was intended to help vulnerable patients by requiring drug manufacturers to provide discounted medications to covered entities. But as Bill puts it, has the program strayed too far from its patient-first mission? With explosive growth, patchwork state laws, opaque data, and billions on the line, is it still doing what it was designed to do—or are the sick paying the ultimate price?
🔍 In this episode, we explore:
✅ How 340B ballooned from a modest program to a behemoth that may soon outpace Medicare Part D
✅ Why transparency remains elusive—and who’s resisting it
✅ The uncomfortable reality: charity care rates at major hospitals vs. billions in 340B profits
✅ The looming risks to rare disease innovation and patient access
✅ Bill’s insider perspective on why patients often aren’t seeing the savings
✅ What changes might be coming from state houses, courts, and possibly Washington
Bill also shares candid insights from his own journey as a rare disease patient—and why that makes him both more hopeful and more skeptical than ever.
💡 Links & Resources Mentioned
Bill Sarraille on LinkedIn: https://www.linkedin.com/in/william-sarraille-634a8827/
ADAP Advocacy Association: https://www.adapadvocacy.org/
340B Report (for policy resources & updates): https://340breport.com/
View all episodes
By RealPharma
5
1212 ratings
🎙️ 340B or Bust: Is This Program Failing the Sick?
This week on Real Pharma, hosts Dr. Na-Ri Oh and Ian Wendt dive into the tangled world of 340B with returning guest William “Bill” Sarraille—one of the most respected voices in healthcare law, an active patient advocate, and a rare disease patient himself.
The 340B Drug Pricing Program was intended to help vulnerable patients by requiring drug manufacturers to provide discounted medications to covered entities. But as Bill puts it, has the program strayed too far from its patient-first mission? With explosive growth, patchwork state laws, opaque data, and billions on the line, is it still doing what it was designed to do—or are the sick paying the ultimate price?
🔍 In this episode, we explore:
✅ How 340B ballooned from a modest program to a behemoth that may soon outpace Medicare Part D
✅ Why transparency remains elusive—and who’s resisting it
✅ The uncomfortable reality: charity care rates at major hospitals vs. billions in 340B profits
✅ The looming risks to rare disease innovation and patient access
✅ Bill’s insider perspective on why patients often aren’t seeing the savings
✅ What changes might be coming from state houses, courts, and possibly Washington
Bill also shares candid insights from his own journey as a rare disease patient—and why that makes him both more hopeful and more skeptical than ever.
💡 Links & Resources Mentioned
Bill Sarraille on LinkedIn: https://www.linkedin.com/in/william-sarraille-634a8827/
ADAP Advocacy Association: https://www.adapadvocacy.org/
340B Report (for policy resources & updates): https://340breport.com/
More shows like RealPharma: Conversations with Pharma Pathfinders
View all
Wait Wait... Don't Tell Me!
38,892 Listeners
The NPR Politics Podcast
26,019 Listeners
WSJ What’s News
4,413 Listeners
HBR IdeaCast
155 Listeners
The Daily
113,475 Listeners
Bold Names
1,448 Listeners
It's Been a Minute
9,112 Listeners
The Readout Loud
336 Listeners
Behind the Money
238 Listeners
The Journal.
6,105 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,233 Listeners
BioCentury This Week
35 Listeners
F1 Nation
773 Listeners
SmartLess
58,523 Listeners
Hard Fork
5,595 Listeners